Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphangioleiomyomatosis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 9 Recurrence 4 Ovarian Neoplasms 4 Glioblastoma 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Small Cell Lung Carcinoma 2 Radiation Pneumonitis 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Fallopian Tube Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumors 1 Rectal Neoplasms 1 Patients With Any Advanced Solid Tumors 1 Pancreatic Neoplasms 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasms 1 Mesothelioma, Malignant 1 Melanoma, Cutaneous Malignant 1 Lymphangioleiomyomatosis 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Esophagogastric Adenocarcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1

Interventions

Sirolimus 9 Everolimus 3 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 nintedanib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Glutamine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03062943 2022-09-28

LAM

IRCCS Multimedica

Phase 2 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡